Printer Friendly

HCA Healthcare price target raised to $114 from $97 at Argus.

Argus analyst Jasper Hellweg raised his price target on HCA Healthcare to $114 and kept his Buy rating after Q4 earnings, pointing to the company's strong guidance, positive impact of U.S. tax changes, and expanding business. The analyst also initiates a FY19 EPS view of $9.26, which implies a 8.4% increase from his expected FY18 forecast in addition to his modeled 11% rise in FY19 revenue. Hellweg adds that the company has been able to respond to greater competition in the commercial market and a less favorable payer mix with acquisitions and the strategic use of big data.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Feb 12, 2018
Previous Article:Catalyst Pharmaceuticals announces plans to resubmit NDA for Firdapse.
Next Article:E2open submits proposal to acquire Amber Road for $10.50 per share in cash.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters